Xenetic Biosciences Reports Revenue Growth Driven by Royalty Income in Q2 2026

Xenetic Biosciences, Inc. reported its financial results for the second quarter and first half of 2026, revealing a revenue increase driven primarily by royalty income. For the three months ended June 30, 2026, the company generated total revenue of approximately $660,601, a 12% increase from $589,897 in the same period of 2025. For the six months ended June 30, 2026, total revenue rose to $1,467,524, up 24% from $1,183,158 year-over-year. The increase in revenue is attributed to higher royalty payments from its sublicense agreement with Takeda Pharmaceuticals, reflecting improved sales in certain markets.

Despite the revenue growth, Xenetic reported a net loss of $929,695 for the second quarter of 2026, compared to a loss of $688,703 in the prior year, marking a 35% increase in losses. For the first half of 2026, the net loss was $1,386,077, a decrease of 12.9% from $1,591,844 in the same period of 2025. The company's operating expenses rose to $1,632,291 for the second quarter, a 24.2% increase from $1,314,309 in 2025, primarily due to a significant rise in general and administrative expenses, which increased by 64.2% to $1,080,278, largely driven by legal costs associated with a strategic review process.

In terms of operational developments, Xenetic has initiated a formal strategic review process to explore various alternatives aimed at maximizing shareholder value. This includes potential sales of the company or its assets, as well as business combinations. The board of directors has engaged outside financial and legal advisors to assist in this process, although no definitive timeline or proposals have been established. The company remains committed to advancing its proprietary DNase technology, which is focused on treating difficult cancers, including pancreatic carcinoma.

As of June 30, 2026, Xenetic's total assets were approximately $6.97 million, down from $8.36 million at the end of 2025. The company’s cash reserves decreased to $6.47 million from $7.88 million, while current liabilities were reduced to $894,977 from $968,025. The accumulated deficit increased to $201.26 million, reflecting ongoing operational losses. The company’s working capital also declined to $5.8 million, down from $7.1 million at the end of the previous fiscal year.

Looking ahead, Xenetic anticipates the need for additional capital to support its business initiatives, despite currently having sufficient resources to fund operations for at least the next twelve months. The company is exploring various financing options, including public or private equity offerings and corporate collaborations. However, the timing and terms of any future financing will depend on multiple factors, including market conditions and the progress of its product development programs.